Xilio Therapeutics (XLO) Depreciation and Depletion (2020 - 2026)

Xilio Therapeutics has disclosed Depreciation and Depletion across 7 years of filings, most recently posting $300000.0 for Q1 2026.

• Depreciation and Depletion for Q1 2026 came in at $300000.0, down 40.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 million (down 23.53% YoY), and the FY2025 annual result was $1.5 million, down 6.25% from the prior year.
• Depreciation and Depletion came in at $300000.0 for Q1 2026 at Xilio Therapeutics, roughly flat from $300000.0 in the prior quarter.
• In the past five years, Depreciation and Depletion ranged from a high of $500000.0 in Q3 2022 to a low of $300000.0 in Q3 2025.
• The 5-year median for Depreciation and Depletion is $400000.0 (2022), against an average of $405882.4.
• Across the five-year window, Depreciation and Depletion surged 66.67% in 2022 and tumbled 40.0% in 2026, its largest moves.
• Xilio Therapeutics' Depreciation and Depletion stood at $400000.0 in 2022, then changed by 0.0% to $400000.0 in 2023, then changed by 0.0% to $400000.0 in 2024, then declined by 25.0% to $300000.0 in 2025, then changed by 0.0% to $300000.0 in 2026.
• The last three Depreciation and Depletion figures came in at $300000.0 (Q1 2026), $300000.0 (Q4 2025), and $300000.0 (Q3 2025), per Business Quant data.